ActoKine Therapeutics is positioned as a niche research and discovery biotechnology company, with a unique business model of working with leading pharmaceutical companies to discover novel functions of existing drugs (drug rescue & drug indication switch). ActoKine will perform new discovery research on such drugs for the pharmaceutical company in exchange for an initial milestone payment upon pre-clinical verification of the new indications, additional milestone payments in later drug development stages, and royalty payments.

In addition to cancer therapy, ActoKine will also discover novel functions of known drugs and new drug delivery for protein drugs in various diseases to open up new niche markets. ActoKine expects a faster path to commercialization using advanced and existing drug development, known status of drug toxicity, leveraging existing knowledge and product availability. ActoKine is looking at a much shorter time to product launch than a typical biotech startup.